A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1)

Booton, Richard; Lorigan, Paul; Anderson, Heather; Baka, Sofia; Ashcroft, Linda; Nicolson, Marianne; O’Brien, Mary; Dunlop, David J.; O’Byrne, Kenneth J.; Laurence, V.; Snee, M.; Dark, Graham; Thatcher, Nick

doi:10.1093/annonc/mdl078

Cited by 53 publications

(42 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The docetaxelplatinum arms were also associated with improved tolerability, resulting in fewer grades 3 and 4 adverse events (aes) than resulted with vinorelbine-cisplatin. Those findings were consistent with findings in other phase iii trials comparing docetaxel-platinum combinations with other chemotherapy regimens 8,10,[19][20][21] . The most common grades 3 and 4 aes reported with docetaxel-platinum combinations were neutropenia, leucopenia, and nausea and vomiting 8,10,[19][20][21] .…”

Section: Introductionsupporting

confidence: 91%

Update on Taxanes in the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Socinski¹

2014

Current Oncology

View full text Add to dashboard Cite

standard-of-care options, and no single standardof-care regimen is superior in the treatment of advanced nsclc 7-10 . Thus, physicians rely on numerous factors to optimize treatment strategies, including histology, age, performance status, cost, tolerability, and convenience. The combination of a platinum agent with a taxane-either solvent-based (sb) paclitaxel (Taxol: Bristol-Myers Squibb, Princeton, NJ, U.S.A.) or docetaxel (Taxotere: SanofiAventis, Bridgewater, NJ, U.S.A.)-has a proven efficacy and safety profile in advanced nsclc 6 . The sb-paclitaxel-carboplatin regimen is among those most commonly used for the first-line treatment of advanced nsclc in the United States 11 .Recently, nab-paclitaxel, a 130-nm albuminbound ("nab") form of paclitaxel designed to use endogenous albumin pathways to increase intratumoural concentrations of the active drug, demonstrated improved antitumour activity and tolerability compared with sb-paclitaxel when both were used in combination with carboplatin in the first-line treatment of patients with advanced nsclc 12 . Based on the results of a phase iii trial, nab-paclitaxel in combination with carboplatin was approved in 2012 as first-line therapy for the treatment of locally advanced or metastatic nsclc in patients who are not candidates for curative surgery or radiation therapy 12,13 . The present review summarizes the clinical experience to date with taxanes in the first-line treatment of nsclc. DISCUSSION Taxane-Platinum CombinationsIn landmark nsclc studies, overall response rates (orrs) were higher with taxane-platinum combinations than with other chemotherapy regimens ( Table i). Historically, sb-paclitaxel given in combination with carboplatin or cisplatin demonstrated a median overall survival (os) of 7.7-10 months and an orr of 17%-41% [7][8][9]11,14,[16][17][18]22 . ABSTRACTBased on demonstrated favourable risk-benefit profiles, taxanes remain a key component in the first-line standard of care for advanced non-smallcell lung cancer (nsclc) and nsclc subtypes. In 2012, a novel taxane, nab-paclitaxel (Abraxane: Celgene Corporation, Summit, NJ, U.S.A.), was approved, in combination with carboplatin, for the first-line treatment of locally advanced or metastatic nsclc. The approval was granted because of demonstrated improved antitumour activity and tolerability compared with solvent-based paclitaxelcarboplatin in a phase iii trial. This review focuses on the evolution of first-line taxane therapy for advanced nsclc and the new options and advances in taxane therapy that might address unmet needs in advanced nsclc.

show abstract

Section: Introductionsupporting

confidence: 91%

Update on Taxanes in the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Socinski¹

2014

Current Oncology

View full text Add to dashboard Cite

show abstract

“…Cisplatin or carboplatin have been proven effective in combination with any of the following agents: docetaxel, etoposide, gemcitabine, irinotecan, paclitaxel, pemetrexed, vinblastine, and vinorelbine. 188,[203][204][205][206]209,210 New agent/nonplatinum regimens are reasonable alternatives if available data show activity and tolerable toxicity (e.g., gemcitabine/docetaxel). 211 No evidence yet shows the superiority of one particular platinum-based regimen.…”

Section: Treatment Of Recurrences and Distant Metastasesmentioning

confidence: 99%

“…Despite the development of new chemotherapy regimens, the prognosis for advanced inoperable lung cancer remains poor. Other carboplatinbased regimens include gemcitabine/carboplatin and docetaxel/carboplatin; 203,209,210 gemcitabine/docetaxel is another option. 211 Note that albumin-bound paclitaxel can be substituted for paclitaxel or docetaxel either for patients who have experienced hypersensitivity reactions after receiving paclitaxel or docetaxel despite premedication, or those in whom the standard premedications (i.e., dexamethasone, H2 blockers, H1 blockers) are contraindicated.…”

mentioning

confidence: 99%

Non–Small Cell Lung Cancer

Ettinger

Akerley

Bepler

et al. 2010

J Natl Compr Canc Netw

604

371

View full text Add to dashboard Cite

show abstract

“…No significant differences were detected in survival, with median survival 9.5 months for carboplatin/docetaxel and 8.7 months for the control arm (P = 0.295), and one-year survival 39% and 35%, respectively. Despite the fact that significantly more patients on the carboplatin/ docetaxel arm experienced grade 3 or 4 neutropenia, infection, and mucositis, quality of life analyses indicated an advantage with carboplatin/docetaxel over the reference chemotherapy [25]. • Belani and colleagues compared carboplatin and paclitaxel to cisplatin with etoposide in 369 patients with advanced NSCLC.…”

Section: Metastatic Diseasementioning

confidence: 99%

Cisplatin Versus Carboplatin in NSCLC: Is There One “Best” Answer?

Sanborn

2008

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Platinum-based chemotherapeutic doublets have produced significant survival benefits for patients with non-small cell lung cancer of all disease stages. The optimal combination of chemotherapy has been the subject of much investigation, and the ideal platinum agent the subject of ongoing and heated debate. For patients with resected disease, all evidence of survival advantage rests with cisplatin, and the only clinical trial to evaluate carboplatin-based therapy failed to show a survival benefit. In the setting of locally advanced lung cancer, no comparative data exist, and even randomized phase III trials are largely lacking. Cisplatin-based doublets provide the most consistent evidence of superior survival when coupled with definitive thoracic radiation. Meta-analyses of palliative chemotherapy indicate consistent survival advantages with cisplatin-based therapy over carboplatin; however, the relative advantage is small. Cisplatin carries a higher toxicity profile, including nausea, vomiting, neuropathy, renal insufficiency, and alopecia in comparison to carboplatin. When the goal of therapy is curative, the survival benefits with cisplatin are in most circumstances worth the increased toxicities. When the goal of therapy is palliation, the relative price of toxicity needs to be weighed on the basis of the individual patient in an effort to maximize quality of life.

show abstract

A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1)

Cited by 53 publications

References 38 publications

Update on Taxanes in the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Update on Taxanes in the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

Non–Small Cell Lung Cancer

Cisplatin Versus Carboplatin in NSCLC: Is There One “Best” Answer?

Contact Info

Product

Resources

About